Conclusion: These results demonstrate that the CCL2‐CCR2 axis drives immune cell infiltration targeting NMJs in ALS and suggest that these immune pathways can be therapeutically modulated to protect NMJs from denervation. This evidence concerns the gene CCR2 and amyotrophic lateral sclerosis.